CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

J Hematol Oncol. 2019 Aug 22;12(1):85. doi: 10.1186/s13045-019-0771-0.

Abstract

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

Keywords: Acute myeloid leukemia; Antibody-drug conjugate; CD33.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antineoplastic Agents, Immunological / administration & dosage*
  • Female
  • Genotype
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / immunology
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / immunology
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • RNA Splicing
  • Sialic Acid Binding Ig-like Lectin 3 / genetics*
  • Sialic Acid Binding Ig-like Lectin 3 / immunology*
  • Survival Rate
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • CD33 protein, human
  • Immunoconjugates
  • Sialic Acid Binding Ig-like Lectin 3
  • lintuzumab